AAB-001 in Patients With Mild to Moderate Alzheimer's Disease

A Phase IIA, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Immunogenicity Trial of AAB-001 in Patients With Mild to Moderate AD

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00112073

Enrollment

234

Registered

2005-05-30

Start date

2005-04-30

Completion date

2008-12-31

Last updated

2012-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's Disease

Keywords

Alzheimer's disease, immunotherapy, beta amyloid

Brief summary

The purpose of this study is to assess the safety and tolerability of multiple doses of AAB-001 passive immunization in patients with mild to moderate Alzheimer's disease (AD).

Detailed description

The humanized monoclonal antibody, AAB-001, which binds to and clears beta amyloid peptide, is designed to provide antibodies to beta amyloid directly to the patient, rather than requiring the patient to mount his/her own individual response. It is believed that this approach may eliminate the need for the patient to mount an immune response to beta amyloid. Animal studies have shown that this approach is equally effective in clearing beta amyloid from the brain as traditional active immunization methods. This is a multicenter, double-blind, placebo controlled, randomized, outpatient, multiple ascending dose study in male and female patients aged 50 to 85 years with mild to moderate AD. Approximately 30 study sites will be involved. Patients will be randomized to receive either AAB-001 or placebo. Each patient's participation will last approximately 2 years.

Interventions

DRUGbapineuzumab

IV, Q13w

OTHERplacebo

IV Q13w

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

50 Years to 85 Years

Healthy volunteers

Inclusion criteria

* Diagnosis of probable AD * Age from 50 to 85 years * Rosen Modified Hachinski Ischemic score less than or equal to 4 * Magnetic resonance imaging (MRI) scan consistent with the diagnosis of AD * Fluency in English * Stable doses of medications

Exclusion criteria

* Significant neurological disease other than AD * Major psychiatric disorder * Significant systemic illness * History of stroke or seizure * Weight greater than 120 kg (264 lbs.) * History of autoimmune disease * Smoking more than 20 cigarettes per day * Anticonvulsants, anti-Parkinson's, anticoagulant, or narcotic medications * Prior treatment with experimental immunotherapeutics or vaccines for AD * Presence of pacemakers or foreign metal objects in the eyes, skin, or body

Design outcomes

Primary

Measure	Time frame
safety assessments	18 months

Secondary

Measure	Time frame
blood levels of administered study drug	18 months
cognitive and functional assessments	18 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 25, 2026